Company Analysis
Sign in

Equillium, Inc. (EQ)

Nasdaq: EQ · Pharmaceutical Preparations · La Jolla, CA · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.9
◀ Past 5.1● Present 5.9▶ Future 6.7
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

9 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Equillium, Inc.’s names, not what it holds today.

Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 2 in 2023
Applications published
20
1 of them in 2025
Names they are printed under
4
a subsidiary, its own name
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
ARIAGEN, INC. a subsidiary
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in CA)
7 granted
14 published
Equillium, Inc. its own name
named as the applicant on its applications, in US
0 granted
4 published
BIONIZ THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
2 granted
0 published
BIONIZ THERAPEUTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 9, 202412,030,936Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disordersPharmaceuticalsBIONIZ THERAPEUTICS, INC.
Dec 5, 202311,834,519Compositions and methods for modulating γ-c-cytokine activityPharmaceuticalsBIONIZ THERAPEUTICS, INC.
Jan 10, 202311,547,698Aryl hydrocarbon receptor modulatorsPharmaceuticalsARIAGEN, INC.
Oct 4, 202211,459,322Indole compounds and their useOrganic fine chemistryARIAGEN, INC.
Aug 30, 202211,427,576Indole compounds and their useOrganic fine chemistryARIAGEN, INC.
Jul 19, 202211,390,621Chiral indole compounds and their usePharmaceuticalsARIAGEN, INC.
Apr 28, 202010,632,106Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl esterPharmaceuticalsARIAGEN, INC.
Feb 5, 201910,195,182ITE for cancer intervention and eradicationPharmaceuticalsARIAGEN, INC.
Sep 25, 201810,081,610Efficient and scalable synthesis of 2-(1′h-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester and its structural analogsOrganic fine chemistryARIAGEN, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jan 30, 20252025/0034272COMPOSITIONS AND METHODS FOR TREATING SEVERE ASTHMAPharmaceuticalsEquillium, Inc.
Sep 26, 20242024/0317848MODULATING THE EFFECTS OF GAMMA-C-CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA ASSOCIATED DISORDERSPharmaceuticalsBIONIZ THERAPEUTICS, INC.
Jun 27, 20242024/0209025COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITYPharmaceuticalsBIONIZ THERAPEUTICS, INC.
Feb 15, 20242024/0053360METHODS OF SELECTIVELY TARGETING CD6 HIGH CELLS AND DECREASING ACTIVITY OF TEFF CELLSAnalysis of biological materialsEquillium, Inc.
May 11, 20232023/0145074Indole Compounds and Their UseOrganic fine chemistryARIAGEN, INC. · patent 11,891,386 granted from it
Feb 23, 20232023/0054194Methods of Treating CancerPharmaceuticalsARIAGEN, INC.
Dec 8, 20222022/0389002Chiral Indole Compounds and Their UsePharmaceuticalsARIAGEN, INC.
May 12, 20222022/0143140ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING LUPUSPharmaceuticalsEquillium, Inc.
Dec 9, 20212021/0380711ANTI CD6 ANTIBODIES FOR TREATING SEVERE ASTHMAPharmaceuticalsEquillium, Inc.
Nov 11, 20212021/0347794Phosphate Derivatives of Indole Compounds and Their UsePharmaceuticalsARIAGEN, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton EQ · research, not advice